{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:33Z","timestamp":1788922113284,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Gastric cancer, one of the most common cancers of the digestive tract, has high incidence and mortality rates. Until recently, surgery has been the most effective method of treatment for gastric cancer. Surgery, however, inevitably results in dysfunction of the autonomic nervous system, entry of tumor cells into the bloodstream, and immunosuppression during the perioperative period, all of which increase the risk of complications in patients with gastric cancer. Opioid receptors play an important role in the proliferation and secretion of cytotoxic factors by immune cells. Opiate usage inhibits immune cell function, reduces the release of cytotoxic factors, and enables tumor cells to evade the immune system, thereby increasing the risk of perioperative complications. Opioid antagonists may reverse opioid-mediated immunosuppression in several ways. However, studies on the molecular biology of opioid receptor antagonists in relation to their ability to improve immune function in patients with gastric cancer are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We first analyzed the cancer genome atlas stomach adenocarcinoma (TCGA-STAD) dataset to determine the correlation between changes in immune function and toll-like receptor 4 (TLR4) expression in patients with gastric cancer. A transwell co-culture system was established using CD8<jats:sup>+<\/jats:sup>T and mouse forestomach carcinoma (MFC) cells. CD8<jats:sup>+<\/jats:sup>T cells were treated with different concentrations of naloxone to determine the most effective concentration for killing the tumor cells. We then performed western blotting and quantitative realtime polymerase chain reaction to determine the expression of lymphocyte activation gene 3 (Lag3), perforin 1 (Prf1), programmed death ligand 1 (PD-1), T-cell immunoglobulin and mucin domain 3 (TIM-3), and TLR4\/AKT\/mTOR in CD8<jats:sup>+<\/jats:sup> T cells. An MFC-derived allograft mouse model was used to study the <jats:italic>in vivo<\/jats:italic> changes in the immune cells. Flow cytometry, ELISA, WB, and PCR were used to examine changes in the number of immune cell populations in the spleen, secretion of cytotoxic factors by immune cells, opioid receptors, AKT\/mTOR, and immune checkpoint proteins, respectively, in CD8<jats:sup>+<\/jats:sup>T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that changes in perioperative immune function strongly correlated with TLR4 expression on the surface of immune cells in patients with gastric cancer. Low-dose naloxone (LDN) increased CD8<jats:sup>+<\/jats:sup> T cell cytotoxicity, inhibited CD8<jats:sup>+<\/jats:sup> T cell exhaustion, inhibited Lag3, Prf1, and Tim3 expression, and increased AKT and mTOR expression in CD8<jats:sup>+<\/jats:sup> T cells. Opioid receptors were downregulated in CD8<jats:sup>+<\/jats:sup> T cells following LDN administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LDN improved the ability of CD8<jats:sup>+<\/jats:sup>T cells to kill gastric cancer cells and reduced CD8<jats:sup>+<\/jats:sup>T cell exhaustion. The mechanism underlying these LDN-mediated phenomena may involve regulation of immune checkpoint expression in CD8<jats:sup>+<\/jats:sup> T cells, increased cytotoxic factor secretion by CD8<jats:sup>+<\/jats:sup> T cells via the TLR4\/AKT\/mTOR pathway, or regulation of expression of opioid receptors on CD8<jats:sup>+<\/jats:sup>T cells, thereby further affecting CD8<jats:sup>+<\/jats:sup>T cell exhaustion.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1524930","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T07:35:42Z","timestamp":1742974542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiangzhen","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1615\/JEnvPathToxOncol.v22.i2.70","article-title":"Perioperative immunosuppression in cancer patients","volume":"22","author":"Vallejo","year":"2003","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v10.3","article-title":"Effects of thoracic nerve block on perioperative lung injury, immune function, and recovery after thoracic surgery","volume":"10","author":"Zhang","year":"2020","journal-title":"Clin Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202300102","article-title":"The role of opioid receptors in cancer","volume":"7","author":"Bhoir","year":"2023","journal-title":"Adv Biol (Weinh)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-031-45493-6_4","article-title":"The opioid growth factor in growth regulation and immune responses in cancer","volume":"35","author":"Hankins","year":"2024","journal-title":"Adv Neurobiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrn3858","article-title":"Opioid and chemokine receptor crosstalk: a promising target for pain therapy","volume":"16","author":"M\u00e9lik Parsadaniantz","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116665","DOI":"10.1016\/j.biopha.2024.116665","article-title":"Effects of opioid drugs on immune function in cancer patients","volume":"175","author":"Li","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1134744","article-title":"Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis","volume":"13","author":"Sun","year":"2023","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100010","DOI":"10.1016\/j.bjao.2022.100010","article-title":"Opioids and cancer survival: are we looking in the wrong place","volume":"2","author":"Giakomidi","year":"2022","journal-title":"BJA Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.05.020","article-title":"Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy","volume":"61","author":"Li","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/2589977513666210127094222","article-title":"Low doses naltrexone: the potential benefit effects for its use in patients with cancer","volume":"13","author":"Couto","year":"2021","journal-title":"Curr Drug Res Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704577","article-title":"Naloxone prevents cell-mediated immune alterations in adult mice following repeated mild stress in the neonatal period","volume":"135","author":"Loizzo","year":"2002","journal-title":"Br J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.3390\/ijms25052618","article-title":"The role of opioid receptor antagonists in regulation of blood pressure and T-cell activation in mice selected for high analgesia induced by swim stress","volume":"25","author":"Skiba","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"109438","DOI":"10.1016\/j.intimp.2022.109438","article-title":"Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic","volume":"113","author":"McLaughlin","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01928-x","article-title":"Possible mechanism for improving the endogenous immune system through the blockade of peripheral \u03bc-opioid receptors by treatment with naldemedine","volume":"127","author":"Gondoh","year":"2022","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12871-024-02524-7","article-title":"Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial","volume":"24","author":"Min","year":"2024","journal-title":"BMC Anesthesiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.intimp.2016.08.015","article-title":"Functional modulation on macrophage by low dose naltrexone (LDN)","volume":"39","author":"Yi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009962","article-title":"Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma","volume":"12","author":"McIlvried","year":"2004","journal-title":"J Immunotherapy Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7428-3_9","article-title":"Flow cytometry (FCM) analysis and fluorescence-activated cell sorting (FACS) of erythroid cells","volume":"1698","author":"An","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"578534","DOI":"10.1016\/j.jneuroim.2025.578534","article-title":"Morphine's role in macrophage polarization: exploring M1 and M2 dynamics and disease susceptibility","volume":"400","author":"Malik","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i16.2452","article-title":"Updates on global epidemiology, risk and prognostic factors of gastric cancer","volume":"29","author":"Yang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.52547\/ibj.26.1.36","article-title":"TLR2 and TLR4 signaling pathways and gastric cancer: insights from transcriptomics and sample validation","volume":"26","author":"Zargari","year":"2022","journal-title":"Iran BioMed J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"145181","DOI":"10.1016\/j.gene.2020.145181","article-title":"Genetic variants in the regulation region of TLR4 reduce the gastric cancer susceptibility","volume":"767","author":"Li","year":"2021","journal-title":"Gene"},{"key":"B26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12935-018-0682-0","article-title":"Polymorphisms of TGFBR1, TLR4 are associated with prognosis of gastric cancer in a Chinese population","volume":"18","author":"He","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb05440.x","article-title":"The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice","volume":"917","author":"Sacerdote","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12974-017-0804-y","article-title":"Cytotoxic T cells modulate inflammation and endogenous opioid analgesia in chronic arthritis","volume":"14","author":"Baddack-Werncke","year":"2017","journal-title":"J Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2024.08.034","article-title":"Perceptions toward naloxone among patients with cancer receiving opioids","volume":"68","author":"Amaram-Davila","year":"2024","journal-title":"J Pain Symptom Manage"},{"key":"B31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8(+) T cell subsets in antitumor immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2009.08.008","article-title":"Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB\/c mice","volume":"9","author":"Molla Hassan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"215598","DOI":"10.1016\/j.canlet.2022.215598","article-title":"PMN-MDSCs accumulation induced by CXCL1 promotes CD8(+) T cells exhaustion in gastric cancer","volume":"532","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41419-022-04695-y","article-title":"Dopamine D3 receptor signaling alleviates mouse rheumatoid arthritis by promoting Toll-like receptor 4 degradation in mast cells","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.832292","article-title":"Editorial: the role of opioid receptors in immune system function","volume":"12","author":"Rogers","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01455","article-title":"Toll-like receptor 4 (TLR4)\/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/164_2021_441","article-title":"Kappa opioid receptor expression and function in cells of the immune system","volume":"271","author":"Rogers","year":"2022","journal-title":"Handb Exp Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1524930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T07:35:45Z","timestamp":1742974545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1524930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1524930"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1524930","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"article-number":"1524930"}}